Summary Information
Classification Chemicals / Complex Chemical Agents / Type:

(This chemicals section is currently predominantly used in Wildpro to link different data types and demonstrate inter-relationships. It does not contain detailed information on the chemical itself.)

Alternative Names
  • Succinylcholine
  • Succynyldicholine
Notes Information in this page has been entered to support the current volumes of Wildpro and further information will be added as new volumes are completed. This page is not intended to substitute for the manufacturer's data sheet and the information is not yet complete for all species, or for all contra-indications etc.

CAUTION: Before any pharmaceutical product is used, the manufacturer's data sheet, containing information on uses, dosage and administration, contra-indications, warnings etc., should always be consulted. It is important to remember that licensing of pharmaceutical products for use in a particular species/condition, as well as mandatory meat and milk withdrawal times for food-producing animals, varies between countries and changes with time. Withdrawal times also may vary between different pharmaceutical formulations and depending on route of administration. In the EU, the prescription cascade must be followed (see LCofC1.2H and W564.Apr05.w1); note that specific restrictions apply for food-producing animals. In the USA, FARAD may be consulted regarding residues and meat and milk withdrawal times.

  • Depolarising muscle relaxant, used in anaesthesia., with rapid onset and short duration of action. (B683.15.w15)
  • Mimics acetylcholine at the neuromuscular junction, but with slower hydrolysis therefore prolonged depolarisation, which causes neuromuscular blockade. Recovery is spontaneous. (B683.15.w15)
  • Note: Prior to paralysis, painful muscle fasciculations usually occur, therefore this drug should be given after induction of anaesthesia. (B683.15.w15)
  • Single use results in tachycardia, but repeated doses result in bradycardia; in children, bradycardia may develop even with the first dose. (B683.15.w15)
  • Premedication with atropine reduces the bradycardia and the excess salivation. (B683.15.w15)
  • In humans, intravenous doses of about 1 mg/kg produce relaxation for about 2 - 6 minutes. (B683.15.w15)
  • With prolonged administration, dual block may occur - development of nondepolarising block. (B683.15.w15)
  • Individuals with myasthenia gravis are resisant to suxamethonium but may develop dual block and therefore delayed recovery. (B683.15.w15)
  • Individuals with low plasma cholesterase may show prolonged paralysis. (B683.15.w15)
  • Assisted ventilation is required during the period of action until muscle function returns. (B683.15.w15)
  • Potentiated by anticholinesterases such as Neostigmine. (B683.15.w15)
  • Contra-indicated in individuals with a family history of malignant hyperthermia, low plasma cholinesterase (including individuals with severe hepatic disease), hyperkalaemia, severe trauma or burns, neurological disease involving wasting of major muscles, prolonged immobilisation and personal or family history of congenital myotonic disease or Duchenne muscular dystrophy. (B683.15.w15)
  • Caution in pregnant individuals, individuals with cardiac, respiratory or neuromuscular disease, raised intra-ocular pressure (avoid in individuals with penetrating eye injury)  or severe sepsis (risk of hyperkalcaemia. (B683.15.w15)
  • Side-effects can include postoperative muscle pain, myoglobinuria, myoglobinaemia, tachycardia, arrhythmias, cardiac arrest, hypertension or hypotension, bronchospasm, apnoea, prolonged respiratory depression, anaphylactic reactions, hyperkalaemia, hyperthermia, increased gastric pressure, rash, flushed skin. (B683.15.w15)
  • Human: 1 mg/kg intravenously initially, maintenance usually 0.5 - 1.0 mg/kg every 5-10 minutes to a maximum of 500 mg per hour. By infusion, solution containing 1-2 mg/mL (0.1 - 0.2%), at 2.5 - 4.0 mg/minute to a amximum of 500 mg per hour. (B683.15.w15)
    • Neonates and children under one year of age, 2 mg/kg. Children over one year, 1 mg/kg. (B683.15.w15)

Great Apes

Return to Top of Page